Théa Pharma Inc. provides Canadian eye care professionals and patients with  innovative solutions to a wide range of vision conditions

TORONTO , Jan. 10, 2023 /CNW/ — The successful completion of the five-year joint venture between two family-owned specialty attention care companies, Laboratoires Théa (“Théa”) based in France , and Canada’s Labtician Ophthalmics, has given rise to the newly minted Théa Pharma Inc (Théa Pharma Canada), with headquarters in Toronto, Ontario .   Both organizations benefited from their collaboration over the last 5 years and are now well positioned to pursue their distinct specialties. With the goal of becoming Canada’s leading provider of preservative-free eyesight care solutions, Théa Pharma Canada will devote 100 percent of its attention in order to eye care, and to the particular professionals who manage the eye health associated with Canadians across the country.

Théa Pharma Inc. (CNW Group/Théa Pharma Inc. )

Théa Pharma Canada has plans to accelerate its growth and presence in Canada by leveraging the culture plus values from the family-owned and run parent company, Théa, Europe’s top and pioneering eye health brand founded in 1994 by Henri Chibret. In addition to bringing best-in-class eye care solutions in order to Canadian individuals, Théa Pharma Canada plans to embody the spirit of product innovation, professional education plus strong partnerships that have been critical to Théa’s success globally. As an affiliate of a highly successful global entity, Théa Pharma Canada will leverage global reinvestment in R& D to introduce new and novel preservative-free treatments towards the Canadian market, as well as provide access for Canadian eye treatment professionals in order to value-added education, training and other programs led simply by world experts in eyes care.

The transaction, which became effective on January 1 st , 2023, is significant for the particular Company on many levels. “Although our name is new, what will not change will be our long-term commitment to Canadian ophthalmologists, optometrists, plus their sufferers, ” said Fiona McCloskey , General Manager, Théa Pharma North america.   “Canadian eye care professionals have come to rely on us for our cutting-edge preservative-free treatments, but also see us as a valued partner in finding options to an array of ocular conditions including Dry Eye, Lid Margin Disease, Glaucoma, Allergy, and more. We look forward in order to continuing our own partnership with the Canadian eye treatment community inside 2023, and for many years to come, along with the mission to protect and promote the attention wellness of all Canadians. ”

Enabling everyone to keep their own eyes wide open to the world, preserving eyesight and preventing eye disease is usually Théa Pharma Canada’s objective.   According to the Canadian Council of the particular Blind Report commissioned in collaboration with Fighting Blindness Canada, the Canadian Association of Optometrists, and the Canadian Ophthalmological Society, eight million Canadians, almost a quarter of the population, live along with an eye disease that could result in vision loss and blindness. The good news is definitely that early diagnosis plus treatment could help three-quarters of these individuals from losing their particular vision and going blind. i

ABOUT THÉA PHARMA INC.

Théa Pharma Canada  can be an affiliate of Théa, Europe’s leading independent vision care group with a singular focus on the research, development, plus commercialization associated with eye care products. Based in Toronto, Ontario , Théa Pharma Canada’s current portfolio includes products for dry eye  (Thealoz Duo®, Thealoz Duo® Gel, Hyabak®, Thealoz™), lid hygiene (Blephaclean®, Blephagel® Duo), glaucoma (Monoprost®), and allergy (Zaditor®).

Théa Pharma Canada  offers plans in order to launch several products more than the next 12-18 months, including the particular recent Health Canada approved Eyezirgan® for the treatment of ocular herpes simplex keratitis, Zaspray® for the treatment of dry attention associated with allergy, Duokopt®, the combination item for the remedying of glaucoma, and other items in their lid hygiene range.

REGARDING THÉA

Théa  is the top independent European pharmaceutical team in ophthalmology. Based in Clermont-Ferrand, France , it has thirty-five affiliates & offices inside Europe , North plus South America , North Africa , and the Middle East . Today, the network includes more than 1, 600 employees, plus its products are available in 75 countries around the world. In 2021, Théa had global revenues of approximately $773 mil .   The independent and family-owned and run group, started from a Research and Development start-up by Henri Chibret, has been chaired since 2008 by Jean-Frédéric Chibret, his nephew.   To learn more about Théa, visit  https://www.laboratoires-thea.com/en .

SOURCE Théa Pharma Inc.

Cision

Cision

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/January2023/10/c6999.html

Leave a Reply

Your email address will not be published. Required fields are marked *